| Name | Cyclophosphamide |
| Description | Cyclophosphamide is an alkylating agent type of anti-tumor drug, and its main target is DNA. Cyclophosphamide inhibits the proliferation of tumor cells by undergoing alkylation reactions with DNA, interfering with the replication and transcription processes of DNA. |
| In vitro | METHODS: Human HL60 cells were treated with Cyclophosphamide, and cytotoxicity was detected by the MTT method.
RESULTS: Cyclophosphamide inhibited the growth of HL60 cells, with an IC50 of 8.79 μM. [1]
METHODS: Human K562 cells were treated with Cyclophosphamide for 48 hours, and the cell growth inhibition was detected by the MTT method.
RESULTS: Cyclophosphamide inhibited the growth of K562 cells, with an IC50 of 0.153 μM.
METHODS: Human MCF7 cells were treated with Cyclophosphamide for 48 hours, and cytotoxicity was detected using the SRB method.
RESULTS: Cyclophosphamide inhibited the growth of K562 cells, with an IC50 of 10 mM. [2]
METHODS: COS-1 cells and HCT-15 cells were treated with Cyclophosphamide for 24 hours, and cytotoxicity was detected by the MTT method.
RESULTS: Cyclophosphamide inhibited the growth of COS-1 cells (IC50=125.43 μM) and HCT-15 cells (IC50=74.32 μM). [3]
METHODS: DU-145 cells were treated with Cyclophosphamide, and cytotoxicity was detected by the MTT method.
RESULTS: Cyclophosphamide inhibited DU-145 cells (IC50=52.5 μM). [4]
METHODS: HCT-15 cells and HEK-293T cells were treated with Cyclophosphamide for 24 hours, and the cell growth inhibition was detected by the MTT method.
RESULTS: Cyclophosphamide inhibited the growth of COS-1 cells (IC50=76.32 μM) and did not inhibit the growth of HEK-293T cells (IC5> 100 μM). [5] |
| In vivo | METHODS: Cyclophosphamide induces ovarian insufficiency (POI) by activating primordial follicles. Cyclophosphamide (150 mg/kg; Intraperitoneal injection A single dose was injected into 5-week-old female Balb/C mice.
RESULTS: The number of primary follicles in the ovaries decreases. [6]
METHODS: Cyclophosphamide induces bone marrow suppression by interfering with the proliferation and differentiation of bone marrow (BM) cells. Cyclophosphamide (150 mg/kg; Intraperitoneal injection A single dose was injected into 56-week-old male Swiss mice.
RESULTS: It causes significant changes in the structure of bone marrow tissue, reduces the bone marrow/red blood cell ratio, and decreases the number of white blood cells in the blood. [7] |
| Storage | store at low temperature,keep away from direct sunlight,keep away from moisture,The compound is unstable in solution. Please use soon | Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Saline : 20 mg/mL (76.6 mM), Sonication is recommended.
H2O : 20 mg/mL (76.6 mM), Sonication is recommended. The compound is unstable in solution, please use soon.
DMSO : 255 mg/mL (976.67 mM), The compound is unstable in solution, please use soon.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (19.15 mM), Sonication is recommended.
|
| Keywords | MRP1 | Inhibitor | inhibit | DNAAlkylator | DNA Alkylator/Crosslinker | DNA Alkylator | DNA | Cyclophosphamide | Crosslinker |
| Inhibitors Related | Cyclophosphamide hydrate | Streptozotocin | N-Nitroso-N-methylurea | Lisinopril dihydrate | Methoxsalen | 2-Iodoacetamide | Methyl methanesulfonate | Temozolomide | Flurbiprofen | Clarithromycin | Cholesterol | Cisplatin |
United States
